Ph III salmon calcitonin trial completes recruitment

Swiss drug major Novartis has finished recruitment into a multicenter Phase III study exploring the safety and efficacy of salmon calcitonin using USA-based Emisphere Technologies' proprietary Eligen delivery platform in the treatment of vertebral fractures in postmenopausal women aged 60-80 with osteoporosis.

The last of over 4,500 patients was recruited in the final week of June, and the three-year study will be conducted in North and South America, Europe and Asia.

Emisphere noted that Eligen Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhaled, intra-vaginal or transdermal.